Sep. 18, 2021

Molecules of the Month - March 2021

sisunatovir

oral lung penetrant RSV fusion inhibitor Ph. II candidate (50 mg BID) for RSV infect. opt. from literature starting point J. Med. Chem., Mar. 17, 2021 Reviral Ltd, Hertfordshire, UK

twitterlinkedinprintemail